First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients

YÜKSEL, SELÇUK; Evrengul, Havva; ÖZÇAKAR, ZEYNEP; Becerir, Tulay; Yalcin, Nigihan; Korkmaz, Emine; ÖZALTIN, FATİH

doi:10.1007/s40272-016-0194-0

First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients

Copy For Citation

YÜKSEL S., Evrengul H., ÖZÇAKAR Z. B., Becerir T., Yalcin N., Korkmaz E., ...More

PEDIATRIC DRUGS, vol.18, no.6, pp.413-420, 2016 (SCI-Expanded)

Publication Type: Article / Article
Volume: 18 Issue: 6
Publication Date: 2016
Doi Number: 10.1007/s40272-016-0194-0
Journal Name: PEDIATRIC DRUGS
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.413-420
Hacettepe University Affiliated: Yes

Abstract

Studies relating to first-line, early, and long-term eculizumab treatment and outcomes in children with atypical hemolytic uremic syndrome (aHUS) are scarce and unclear. The aim of this case-series study was to evaluate the outcomes of first-line, early, and long-term eculizumab treatment in our aHUS patients.